Skip to main navigation
logo
  • Overview
  • Shareholder Information
    • Stock Quote & Chart
    • Financial Filings
    • Shareholder Structure
    • Shareholder Structure (NL)
    • Shareholder Meetings
    • Analyst Coverage
  • Events & Presentations
  • News
  • Corporate Governance
    • Governance Overview
    • Governance Overview (NL)
    • Board of Directors
    • Management
  • IR Contact
    • Email Alerts
    • Contact IR

News

News

March 17, 2022
Oxurion Receives Transparency Notifications from Fidelity Management & Research Company LLC and Novartis Pharma AG
PDF Version
NL
March 7, 2022
Oxurion Successfully Closes EUR >10 Million in Private Placement
PDF Version
March 3, 2022
Oxurion succesfully raises EUR >10 MILLION from leading US and European healthcare investors in a private equity placement
PDF Version
NL
February 22, 2022
Information on the Total Number of Voting Rights (Denominator) following conversion notices from NEGMA
PDF Version
NL
February 22, 2022
Oxurion NV announces 2021 Full Year Results and 2022 Outlook
PDF Version
NL
February 14, 2022
Oxurion Announces New Data on THR-149 Phase 2 Clinical Trial (“KALAHARI”) in DME at the Angiogenesis, Exudation, and Degeneration 2022 Conference
PDF Version
February 11, 2022
Oxurion Announces Upcoming Presentation on THR-149 Phase 2 Clinical Trial (“KALAHARI”) at the Angiogenesis, Exudation, and Degeneration 2022 Conference
PDF Version
February 8, 2022
Oxurion to Participate in the 2022 BIO CEO and Investor Conference
PDF Version
January 18, 2022
OXURION to Participate in the 10th edition of Degroof Petercam’s Healthcare Conference
PDF Version
January 7, 2022
Oxurion Provides Update on Clinical Pipeline Progress
PDF Version

Pagination

  • First page « first
  • Previous page ‹ previous
  • Page 1
  • Page 2
  • Current page 3
  • Page 4
  • Next page next ›
  • Last page last »
Displaying 21 - 30 of 31

Section Title

  • Who We Are
  • THR-149
  • News & Events
  • Let’s Talk

Connect with Us

  • LinkedIn
  • Twitter
  • Ⓒ2022 Oxurion NV. All rights reserved.